Advanced Therapy Medicinal Products CDMO Market - Global Forecast 2025-2032

The Advanced Therapy Medicinal Products CDMO Market is evolving rapidly, driven by technological advancements, regulatory shifts, and strategic partnerships. This landscape demands agile, scalable solutions from service providers to support the development and commercialization of next-generation therapies.

Market Snapshot: Global Growth and Opportunity in Advanced Therapy Medicinal Products CDMO

The global Advanced Therapy Medicinal Products CDMO Market grew from USD 7.71 billion in 2024 to USD 8.97 billion in 2025 and is projected to reach USD 28.46 billion by 2032, at a compound annual growth rate (CAGR) of 17.71%. Senior decision-makers should note that this rapid expansion is shaped by scientific breakthroughs, regulatory developments, and increasing investment in scalable contract manufacturing.

Scope & Segmentation: Advanced Therapy CDMO Market Coverage

• Product Types: Cell Therapy Products (Non-stem Cell Therapy, Stem Cell Therapy), Gene Therapy Products (Germline Therapy, Somatic Gene Therapy), Tissue Engineered Products
• Service Types: Analytical Testing & Quality Control, Manufacturing Services, Process Development Services, Regulatory & Compliance Support
• Therapeutic Areas: Cardiology, Dermatology, Hematology, Neurology, Oncology
• Applications: Clinical Stage, Commercial Stage
• End-Users: Academic & Research Institutes, Biopharmaceutical Companies
• Geographical Regions:
  • Americas: United States, Canada, Mexico, Brazil, Argentina, Chile, Colombia, Peru
  • Europe, Middle East & Africa: United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland, United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel, South Africa, Nigeria, Egypt, Kenya
  • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan
• Leading Companies: Abzena, Advanced Therapies LLC, AGC Inc., Aldevron, Almac Group, Bio Elpida by Polyplus, BlueReg, Catalent Inc., CELONIC Group, CGT Catapult, Charles River Laboratories International Inc., Coriolis Pharma Research GmbH, Curia Global Inc., Eurofins Scientific SE, FUJIFILM Diosynth Biotechnologies, Lonza Group, Minaris Regenerative Medicine, Oxford Biomedica PLC, Patheon by Thermo Fisher Scientific Inc., Recipharm AB, Rentschler Biopharma SE, REPROCELL Inc., RoslinCT, Samsung Biologics, VIVEBIOTECH S.L.

Key Takeaways: Strategic Insights for Advanced Therapy CDMO Stakeholders

• Continuous manufacturing and single-use bioreactors are now integral to advanced therapy production, increasing operational flexibility and accelerating scale-up.
• Collaboration between CDMOs, biotech developers, and academic partners enhances innovation, enabling faster clinical translation and responsiveness to diverse therapy pipelines.
• Harmonized global regulatory frameworks support predictable, expedited approval pathways, encouraging robust process characterization and investment in compliance.
• Expansion into multi-regional manufacturing, particularly in cost-efficient Asia-Pacific markets, addresses regional demand and reduces risk from supply chain interruptions.
• Service differentiation—spanning analytical, regulatory, and manufacturing support—enables tailored packages for biopharma and academic clients, improving project outcomes.

Tariff Impact: Navigating Regulatory and Cost Pressures

United States tariff measures implemented in 2025 have increased cost pressures throughout the advanced therapy supply chain. Firms are responding with diversified procurement, nearshoring initiatives, and heightened risk management to maintain supply chain resilience. Integrated analytics and regional manufacturing strategies now play a key role in ensuring continued operational continuity and cost efficiency.

Methodology & Data Sources

This analysis incorporates primary interviews with executives from CDMOs, biopharmaceutical companies, regulatory bodies, and raw material suppliers, alongside reviews of peer-reviewed literature, industry white papers, regulatory guidelines, and public disclosures. Quantitative and qualitative insights are cross-validated using data triangulation and scenario analysis techniques.

Why This Report Matters for Decision-Makers

• Provides a clear overview of essential segmentation, market trajectories, and technological adoption shaping the Advanced Therapy Medicinal Products CDMO Market.
• Identifies regulatory, operational, and supply chain dynamics to support strategic planning and risk mitigation for new or existing investments.
• Benchmarks proven approaches and leading company capabilities, arming executives with actionable recommendations for competitive positioning.

Conclusion

This report delivers actionable insights on the evolving contract development and manufacturing environment for advanced therapies. Senior leaders can leverage these findings to inform investment, partnership, and operational strategies in a dynamic and competitive market.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.